Insilico Medicine Announces Strategic Collaboration with Takeda for AI-Driven Drug Discovery

Stock News07-02

Insilico Medicine (03696) has announced that the company has entered into a strategic collaboration agreement with Takeda Pharmaceutical Co Ltd (TAK).

The partnership will leverage Insilico's proprietary end-to-end Pharma.AI platform to advance the discovery of candidate drugs in selected therapeutic areas chosen by Takeda. The goal of the collaboration is to identify novel drug candidates with potential for clinical differentiation by targeting high-potential therapeutic targets.

Under the terms of the agreement, Insilico will lead the AI-driven drug discovery efforts, responsible for identifying candidate molecules meeting predefined scientific and early-development criteria. Takeda will contribute its extensive global development capabilities to advance the clinical validation of the resulting candidate drugs.

Financially, Insilico is set to receive approximately $60 million in upfront and near-term milestone payments. The company is also eligible for additional milestone payments tied to preclinical, clinical, commercial, and sales progress, with the total potential deal value reaching up to approximately $600 million. Furthermore, Insilico is entitled to receive tiered royalty payments based on future net sales following the commercialization of any products.

In return, Takeda will secure exclusive global rights for the development, manufacturing, and commercialization of any novel therapies discovered through this collaboration.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1126358006?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-07-02 08:50","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1126358006","market":"other","top_or_hot":-1,"title":"Insilico Medicine Announces Strategic Collaboration with Takeda for AI-Driven Drug Discovery","media":"Stock News","content":"<p>Insilico Medicine (<b>03696</b>) has announced that the company has entered into a strategic collaboration agreement with Takeda Pharmaceutical Co Ltd (<b>TAK</b>).<br><br>The partnership will leverage Insilico's proprietary end-to-end Pharma.AI platform to advance the discovery of candidate drugs in selected therapeutic areas chosen by Takeda. The goal of the collaboration is to identify novel drug candidates with potential for clinical differentiation by targeting high-potential therapeutic targets.<br><br>Under the terms of the agreement, Insilico will lead the AI-driven drug discovery efforts, responsible for identifying candidate molecules meeting predefined scientific and early-development criteria. Takeda will contribute its extensive global development capabilities to advance the clinical validation of the resulting candidate drugs.<br><br>Financially, Insilico is set to receive approximately $60 million in upfront and near-term milestone payments. The company is also eligible for additional milestone payments tied to preclinical, clinical, commercial, and sales progress, with the total potential deal value reaching up to approximately $600 million. Furthermore, Insilico is entitled to receive tiered royalty payments based on future net sales following the commercialization of any products.<br><br>In return, Takeda will secure exclusive global rights for the development, manufacturing, and commercialization of any novel therapies discovered through this collaboration.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Insilico Medicine Announces Strategic Collaboration with Takeda for AI-Driven Drug Discovery</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nInsilico Medicine Announces Strategic Collaboration with Takeda for AI-Driven Drug Discovery\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036600163\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock News </p>\n<p class=\"h-time\">2026-07-02 08:50</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Insilico Medicine (<b>03696</b>) has announced that the company has entered into a strategic collaboration agreement with Takeda Pharmaceutical Co Ltd (<b>TAK</b>).<br><br>The partnership will leverage Insilico's proprietary end-to-end Pharma.AI platform to advance the discovery of candidate drugs in selected therapeutic areas chosen by Takeda. The goal of the collaboration is to identify novel drug candidates with potential for clinical differentiation by targeting high-potential therapeutic targets.<br><br>Under the terms of the agreement, Insilico will lead the AI-driven drug discovery efforts, responsible for identifying candidate molecules meeting predefined scientific and early-development criteria. Takeda will contribute its extensive global development capabilities to advance the clinical validation of the resulting candidate drugs.<br><br>Financially, Insilico is set to receive approximately $60 million in upfront and near-term milestone payments. The company is also eligible for additional milestone payments tied to preclinical, clinical, commercial, and sales progress, with the total potential deal value reaching up to approximately $600 million. Furthermore, Insilico is entitled to receive tiered royalty payments based on future net sales following the commercialization of any products.<br><br>In return, Takeda will secure exclusive global rights for the development, manufacturing, and commercialization of any novel therapies discovered through this collaboration.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"TAK","symbol_name":"武田制药","start_time":0,"source_url":"","article_id":"1126358006","we_media_id":"1036600163","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1126358006","pubTimestamp":1782953422,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Stock News","introduction":"Global Stock News First-Time Broadcast","home_visible":1,"id":"1036600163","head_image":"https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a"},"summary":"Insilico Medicine (03696) has announced that the company has entered into a strategic collaboration agreement with Takeda Pharmaceutical Co Ltd (TAK).The partnership will leverage Insilico's...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"TAK":"武田制药","BK1141":"生命科学工具和服务","03696":"英矽智能","BK4007":"制药"},"translate_title":"Insilico Medicine宣布与武田就人工智能驱动的药物发现进行战略合作","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"TAK":1,"03696":1},"content_text":"Insilico Medicine (03696) has announced that the company has entered into a strategic collaboration agreement with Takeda Pharmaceutical Co Ltd (TAK).The partnership will leverage Insilico's proprietary end-to-end Pharma.AI platform to advance the discovery of candidate drugs in selected therapeutic areas chosen by Takeda. The goal of the collaboration is to identify novel drug candidates with potential for clinical differentiation by targeting high-potential therapeutic targets.Under the terms of the agreement, Insilico will lead the AI-driven drug discovery efforts, responsible for identifying candidate molecules meeting predefined scientific and early-development criteria. Takeda will contribute its extensive global development capabilities to advance the clinical validation of the resulting candidate drugs.Financially, Insilico is set to receive approximately $60 million in upfront and near-term milestone payments. The company is also eligible for additional milestone payments tied to preclinical, clinical, commercial, and sales progress, with the total potential deal value reaching up to approximately $600 million. Furthermore, Insilico is entitled to receive tiered royalty payments based on future net sales following the commercialization of any products.In return, Takeda will secure exclusive global rights for the development, manufacturing, and commercialization of any novel therapies discovered through this collaboration.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"1","news_tag":"corporation","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.45.2","shortVersion":"4.45.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1126358006","isCrawlerRequest":true}